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Pseudomonas aeruginosa causes acute nosocomial as well as community 
acquired pneumonia.  In cystic fibrosis patients, this organism causes recurrent infections 
and inflammation with a high rate of morbidity and mortality. To support research in 
elucidating the molecular mechanisms of Pseudomonas elastase (PE) on disease 
progression, PE was expressed in E. coli and the protein purified for further application. 
This study represents a valid experimental protocol to produce. Genomic DNA was 
isolated from P. aeruginosa and selected regions were amplified using PCR with lasB 
gene specification. Amplified DNA was ligated into plasmids and E. coli were 
transformed to support the recombinant vector and produce a viable elastase product. The 
recombinant DNA was sequenced and accurately matched the pro-Elastase sequence 
(1497 bp in length). Purification of enzyme produced via heterologous expression in 
ClearColi LPS free E. coli was aided via Ni-NTA Liquid Chromatography system by the 
incorporation of a 6x Histidine affinity tag engineered on the C-terminus of elastase. 
Analysis by SDS-PAGE revealed a product of ~34 kDa in molecular weight consistent 
 vii 
with the molecular weight of the naturally produced mature Elastase. Proteolytic activity 
was determined via Skim Milk Agar diffusion. Elastolytic activity was determined by 
Elastin-Congo Red substrate to be two times the activity of the commercial enzyme. 
Cellular anatomy and physiology experiments confirmed the conserved pathologic effects 
of the Recombinant Elastase. Immunofluorescent study demonstrated preliminary data 
that Recombinant Elastase had the ability to disrupts tight junction structure as evidenced 
by fragmentation of ZO-1 proteins in Calu-3 cell monolayers.
 1 
Chapter One 
 
Introduction 
 
 
Significance and Historical Relevance of Pseudomonas aeruginosa 
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic Gram-negative 
bacterium that typically affects hospitalized patients, presents life-threatening responses 
in hosts with compromised immune systems, and recurrent infections in patients with 
cystic fibrosis (CF) (1, 2). Among other species, P. aeruginosa is normally present in 
small numbers in the human intestines and freely living in water and soil. This organism 
is termed “opportunistic” because it is normally dealt with by the defenses of the body, 
however, when the opportunity arises, as in immunocompromised individuals, it can 
cause local or systemic infection (1). 
 This bacterium was discovered in 1882 by Carle Gessard (2), a chemist and 
bacteriologist from France. Dr. Gessard set out to determine why he kept observing blue 
and green coloration on the bandages of soldiers. He identified water-soluble pigments 
that were derived from the microbe in the pus of infections. These pigments turned blue-
green after exposure to ultra-violet light. He termed this invader Bacillus pyocaneus and 
the cause of “blue pus” that was widely observed throughout many infections, especially 
in children. This bacterium, now known as Pseudomonas aeruginosa (P. aeruginosa), 
possesses the ability to build resistance to most antibiotics making it particularly 
dangerous (3, 4, 5, 6, 7). There are numerous cases of infection by P. aeruginosa since its 
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discovery in 1882, including an epidemic of diarrhea in the 1940s of 24 new-born infants. 
The initial infection was caused by improper sterilization of the milk supply and cleaning 
techniques utilized by the hospital staff (7, 8).  
In 1928, the first true antibiotic, penicillin, was discovered by Alexander Fleming. 
Through his work, he incidentally observed a clearing in petri dishes containing 
Staphylococcus where the mold, Penicillium notatum resided. The clearing zones were 
caused by the production of an antibiotic by the mold which killed any bacteria nearby. 
The United States utilized penicillin in World War II to fight off infection of bacteria in 
battle wounds. However, due to its overuse, severely burned patients frequently displayed 
P. aeruginosa infections that were typically fatal because of the intrinsic ability of P. 
aeruginosa to develop resistance to antibiotics (9). Pseudomonas septicemia had been the 
major cause of death after the initial two-day post-burn period. Statistically, this 
bacterium is the cause of most fatalities from infection post severe burns (10, 11, 12, 13, 
14). In 1954, a study was conducted to determine the epidemiology of this infection 
through the hospital and how to potentially contain the pathogen. Infected burns appeared 
to be the most important reservoirs. About 3 % of the stools of normal subjects and of 
patients with intestinal symptoms carried the organism, which was also isolated from the 
nose, throat, nasopharynx, skin and ear of a small proportion of patients and staff in the 
burns wards. The hands of the nurses were often contaminated with the bacterium which 
would then be spread to various sources through contact (15).  
As the knowledge of this bacterium spread and the concurrent use of antibiotics 
increased, the relevance of P. aeruginosa amplified. Among the list of infections, corneal 
destruction is one of the most commonly observed. After cataract extraction, a ring 
 3 
similar in pigment to intra-capsular cataracts is present in many patients. This was 
determined to be a pyocyaneous infection (P. aeruginosa) and was treated with 
streptomycin therapy because this strain was resistant to penicillin (16). In the cornea, it’s 
been observed that P. aeruginosa causes acute ulceration, hyperacute conjunctivitis, 
infection and scarring (17, 18, 19, 20). 
 Because of P. aeruginosa’s prominence in the hospital environment and post-
surgical procedures, studies were directed to the cause of infection and initial treatment of 
conditions. A major cause for concern has been in pulmonary medicine. In this realm, the 
bacterium contaminates inhalant equipment and becomes a chronic inducer for sustained 
infections with ulcer of the lung epithelium and hemorrhage sequel (21).  
Today’s impact of P. aeruginosa pathogenesis is centered toward patients 
suffering from acute and chronic infections accompanied with a life-threatening injury, 
compromised immune system, or illness, such as Cystic Fibrosis (CF). Patients with CF 
develop chronic infections because the lung epithelium produce thick and sticky mucus 
instead of the typical thin and slippery product. This is due to defective chloride channels 
that prevent chloride from exiting the cell, in turn water is abnormally retained and the 
mucus becomes thick and immotile.  The stagnant mucus becomes a breeding ground for 
bacteria and fungi. The most prevalent bacterium in patients with CF is P. aeruginosa 
which replaces other causative bacteria. There is no cure for CF, but different treatment 
options reduce symptoms and extend life expectancy. Many options include: medications 
such as antibiotics, chest physical therapy, pulmonary rehabilitation, kalydeco (improves 
function of defective channels), and lung transplant. Due to recurrent Pseudomonas 
infections and increase in antibiotic usage in CF patients, P. aeruginosa has become more 
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pathogenic and resistant to drug treatment and options become limited for patients in later 
stages of this disorder (22). Remedies used today to alleviate infection by P. aeruginosa 
include antimicrobial combination drug therapy (beta-lactam antibiotic with an 
aminoglycoside). The family of beta-lactam antibiotics are broad-spectrum and consist of 
penicillin derivatives, cephalosporins, monobactams, and carbapenems. Further, the 
aminoglycoside reduces protein synthesis in Gram-negative bacteria. However, the 
choice of specific antibiotic depends on the site and extent of the infection and on the 
resistance of the present strain (23, 24). Good examples of these therapy interventions 
include the use of the Dutch regimen, an intermittent/combination therapy option in 
which patients are treated with a parenterally administered combination of a β-lactam 
antibiotic with a β-lactamase inhibitor called Piperacillin-tazobactam or the use of TOBI 
podhaler that releases a dry powder directly into the respiratory epithelium (25). 
Furthermore, Azghani and colleagues published work on the use of liposomal antibodies, 
antibodies surrounded by lipids, to increase the effectiveness of antibodies and decrease 
the inhibitory effect in the sputum (26). 
 
Cellular and Molecular Pathogenesis of P. aeruginosa Infection  
Normally, the bacterium doesn’t take up a large amount of the whole microbiome 
in individuals. However, hospitalized patients are at much greater risk for P. aeruginosa 
infection and spreading (1, 2, 27). Thus, when the opportunity arises, this bacterium 
makes use of the susceptible hosts (1, 28). 
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I. Bacterial Adhesion 
A common laboratory reference strain is the P. aeruginosa PAO1, a spontaneous 
chloramphenicol-resistant mutant of the original PAO strain (earlier called “P. 
aeruginosa strain 1”). PAO1 was isolated in 1954 from a wound in Melbourne, Australia 
and provides a genome of reference for one of the most virulent strains isolated from a 
patient and is the most commonly studied strain of P. aeruginosa available (29, 30). 
The first step in P. aeruginosa adhesion is colonization of altered epithelium. 
Once initially adhered, the bacteria begin to expand and divide into mature, stable 
colonies. Many studies describe the use of various pili that allow for complete adherence 
to host cells. Further, it has been shown the flagella and other bacterial products act in 
adhesion as well (31, 32, 33). It was discovered that the flagella and pili are not necessary 
for the initial attachment and formation but do increase the probability of resistance 
development (34). 
 P. aeruginosa is known to produce a biofilm as part of the infection process due 
to chronic infections. The process of biofilm formation begins with the initial infection to 
the surface of tissue, followed by attachment and formation of microcolonies, and lastly 
the biofilm maturation. Once a biofilm is matured in formation, it retains the ability of 
antimicrobial resistance caused by many chronic and persistent infections (35, 36, 37, 
38). The PAO1 strain was utilized in experiments to study the formation of biofilms. A 
Green Fluorescent Protein (GFP) tagged PAO1 wild type elucidated the ability of P. 
aeruginosa to infect hosts by studying the composition and adherence of the bacterium in 
the formation process of mature biofilms (34). 
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II. Virulence Factors of P. aeruginosa 
 Both cell-associated and extracellular products of P. aeruginosa contribute to its 
virulence. Surface structures, including pili and the polysaccharide capsule or glycocalyx, 
appear to mediate the initial attachment of P. aeruginosa to its prospective host, thus 
permitting colonization (31, 39, 40, 41, 42). Extracellular enzymes such as alkaline 
protease, elastase, phospholipase C, and exotoxin A interrupt cellular metabolism, 
degrade infected tissues and promote bacterial invasion. When spreading occurs, 
systemic disease results, often with fatal consequences (39, 40, 43). 
 After years of study by pioneers including Morihara et al., Barbara Iglewski and 
colleagues, it became apparent that the bacterium's virulence depends on many cell-
associated and extracellular factors. An initial break in the skin and mechanical 
boundaries can cause an infection by this bacterium because of its repertoire of virulence 
factors and host compromised immune systems (44, 45, 46). For instance, in vivo studies 
described the use of mutant strains that did not produce exotoxin A, exoenzyme S, 
elastase, or alkaline proteases (47, 48). It was discovered that these elements are 
necessary for P. aeruginosa infection; however, the anatomical location determines the 
ability of any given virulence factor in the infection establishment (47, 48, 49). Various 
strains have adapted to antibiotics and therefore, there is an increased demand for 
studying antimicrobial resistance, mechanisms of virulence including secreted toxins, and 
ability to form biofilms (50, 51, 52). 
III. P. aeruginosa Extracellular Toxins 
The most well-known research on extracellular toxins was performed by Justinus 
Kerner, a German poet, practicing physician, and medical writer was the first to 
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completely and accurately describe the symptoms of botulism and the botulism toxin that 
caused the side-effects such as cramps, vomiting, breathing problems, difficulty 
swallowing, double vision, and weakness or paralysis. Botulism is caused by the 
neurotoxin produced by various strains of the bacterium Clostridium botulinum (53, 54, 
55). Kerner went on to describe a therapeutic use of the botulism toxin based on a set of 
experiments he performed using the toxin in clinical and animal experiments. 
Interestingly, modern developments made by Alan Scott in 1980 have allowed for the 
medicinal purpose of these toxins and are some of the most widely used pharmaceuticals 
in treating patients with strabismus (crossing eyes), cosmetic applications, abnormal 
disorders associated with movement, and even pain (53, 56). 
This observation by Kerner was a huge shift in the understanding of disease and 
infection by bacteria. No longer were bacteria the exclusive cause, but substances 
released by the bacteria were acting in on tissues to allow them to infect, propagate, 
survive and thrive. There are two types of toxins that bacteria can express: exotoxins or 
endotoxins. Exotoxins are directly secreted by bacteria (54, 55). They cause damage to 
tissue of the host by destroying key proteins that maintain tissue structure or cellular 
metabolism. Further, these exotoxins can also be released during lysis of the cell. On the 
other hand, an endotoxin located in the outer membrane of Gram-negative bacteria, also 
known as lipopolysaccharides (LPS), illicit strong responses of inflammation and other 
immune responses when exposed to a host (53, 57). 
Early observations of P. aeruginosa by Morihara’s lab pointed to the production 
of toxins but it wasn’t until the 1970s that these toxins were properly characterized. P. 
aeruginosa produces an expanse of extracellular toxins (exotoxins), which include 
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phytotoxic factor, pigments, hydrocyanic acid, proteolytic enzymes, and phospholipase 
(58, 59). The most important factor in the pathogenicity of P. aeruginosa is the 
elaboration of a group of protein exotoxins including Exotoxin A, the first studied 
exotoxin by this bacterium. This enzyme enters host cells through receptor-mediated 
endocytosis and lands in the cytoplasm where it catalyzes ADP-ribosylation inactivating 
Eukaryotic Translation Elongation Factor 2 (eEF-2), a protein necessary for ribosomal 
function, leading to a standstill in protein biosynthesis and the host cell’s eventual death 
(60, 61, 62). This and the many other exotoxins altogether can produce a variety of 
disease symptoms including leukopenia, acidosis, circulatory collapse, necrosis of the 
liver, pulmonary edema, hemorrhage, and necrosis of kidneys. The proteolytic enzyme, 
P. aeruginosa Elastase, that breaks down peptide bonds of proteins produced by P. 
aeruginosa are responsible for the hemorrhagic and necrotic changes in the skin, as well 
as devastation of the cornea in eye infections. The hemolytic phospholipase C enzyme 
may be responsible for the damage and overall destruction of pulmonary surfactant. 
When this occurs, the result is typically atelectasis or the collapse/closing of the lungs 
(63). This effect, together with inflammatory response and the necrosis of lung 
parenchyma are important in the pathogenesis of the damage to lungs due to 
Pseudomonas-induced pneumonia. Further, it has been implicated that various strains of 
P. aeruginosa produce an enterotoxin responsible for gastrointestinal diseases (54, 55, 
56).  
In 1985, Dr. Iglewski’s team employed a genetic approach to determine the 
contribution of Exotoxin A, exoenzyme S, Elastase and alkaline protease to the 
pathogenesis of P. aeruginosa. They introduced mutations into various strains with 
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chemicals or transposons (48). Pathogenesis of the mutants were then identified using 
immunological, chemical, or toxicity assays to observe their changes and/or increased 
resistance or pathogenesis. Mutants were extensively characterized in vitro to ascertain 
that they were identical to their parent strain except for the production of the desired 
product that could be utilized for further studies as knockouts, knockdowns, or 
dysfunctional for the appropriate exotoxins or enzymes produced. One such model, PAO-
E64, was a mutant that produced an antigenically identical elastase except for its 
deficiency in elastase activity (48, 64). The idea was to better understand how these 
various toxins produced by P. aeruginosa acted alone, together, or in synergy. This 
comparison of the overall function of this bacterium signified infection is not due to a 
single secreted factor alone. As expected, the data indicated that virulence of P. 
aeruginosa is multifactorial and the relative contribution of a given strain (mutation) of 
P. aeruginosa product may vary with the type of infection and the location of tissue 
because of the different cell types and immune responses (44, 64, 65). 
Until the 1960s and 70s, the least-characterized, yet most likely major virulence 
factor, was the trypsin-sensitive, heat-labile exotoxin, P. aeruginosa Elastase. This toxin 
had been shown to be lethal for mice and can elicit hypotensive shock in monkeys and in 
dogs after intravenous administration. Previous investigations in the Liu laboratory 
showed that Elastase inhibits uridine and amino acid uptake by cultured cells and inhibits 
the respiration of mitochondria derived from mouse liver cells (65, 66). The ability of this 
metalloprotease to degrade several extracellular proteins including elastin and collagen 
and functionally inactivate human immunoglobulin G, serum alpha1-proteinase inhibitor, 
and several complement components accentuates its potential importance as a virulence 
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factor (67). Because of the emphasis of my thesis research, the remainder of this 
introduction focuses on the characterization of Elastase, disruption of tight junctions and 
increased epithelial permeability, and the interplay of signal transduction pathways 
involving P. aeruginosa Elastase (PE). 
IV. Characterization of P. aeruginosa Elastase 
 Morihara and his coworkers demonstrated in 1965 that most strains of P. 
aeruginosa produce three distinct proteinases and one, a semialkaline proteinase, 
possesses elastolytic activity as a single homogenous enzyme (68, 69). In vivo studies 
revealed the pathologic effects of purified PE in animal models. Intracutaneous injection 
of PE in microgram amounts had the ability to cause hemorrhage, cellular infiltration of 
the subcutaneous tissue and muscular layer, and degeneration of endothelial cells (70). 
Similar results occurred via intraperitoneal injections in mice causing pulmonary and 
subcutaneous hemorrhaging (71). The production of PE is strain specific and 
accompanied to taxonomic origin (72). Inhibition of elastase was achieved temporarily 
with phosphoramidon, a powerful inhibitor for many proteases and elastases. The 
elastolytic effect was inhibited for a period of twelve hours following the addition of the 
compound to an elastase solution injected into the eyes of rabbits and subcutaneously into 
mice (73, 74). 
 Further biochemical and molecular studies characterized the specific gene coding 
for PE. A DNA fragment from P. aeruginosa was cloned into E. coli via plasmid 
transformation. Deletion mutant analysis confirmed the full-length gene coding for 
elastase must be approximately between 1.0-1.3 Kb in length (75). The DNA segment 
encoding Elastase was cloned and the complete nucleotide sequence was determined in 
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1989. The primary structure of Elastase was determined to be like thermolysin produced 
by Bacillus thermoproteolyticus because the functionally important amino acid sequences 
and residues are identical and both are Zn-metallo proteinases. These proteinases are 
found in many microorganisms but also in snake venom and within the organs and tissues 
of mammals. Mature elastase is an enzyme containing 301 amino acids with a molecular 
mass of 32,926 daltons (33kDa). Further, a “pro” sequence was determined containing 
197 amino acids in length. Initially, Elastase is expressed as an inactive pro-peptide 
similar to other proteases, and this “pro” domain is cleaved in the periplasmic space to 
produce the active Elastase (76, 77, 78). A more in depth molecular characterization of 
the Elastase structural gene (lasB) was performed by Iglewski et al. in 1988. The 
nucleotide sequence of the lasB gene containing 1,491 base pairs encoded a protein of 
498 amino acids with a molecular mass of 53,600 daltons. Using PAO mutants with 
inactive elastase, two structural genes (lasA and lasR) were quantified and verified 
necessary for the activation of the mature elastase (67, 79, 80, 81). LasR was identified as 
a requirement for the transcription of lasB and lasA protein had the ability to enhance the 
elastolytic activity of mature PE (81, 82, 83). 
Pathophysiological Effect of PE 
I. Electrophysiology and Paracellular Permeability 
 Normal respiratory epithelium plays a key role in the immune response to 
pathogens and as a protective barrier against foreign microorganisms and 
macromolecules. During embryogenesis and cell differentiation, layers of epithelium are 
specially developed to create a barrier for the body’s defense and integrity. Along with a 
barrier function, polarized epithelial cells are key to the exchange of ions and water 
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across membranes within the lungs and other tissues (84, 85). However, the normal 
release of minute amounts of exotoxins by a bacterium, such as P. aeruginosa, might 
cause a breach in this barrier increasing the susceptibility to bacterial invasion and 
infection. One in vivo study sought to elucidate this idea and observed the effect of PE on 
the lungs of guinea pigs. This demonstrated that aerosols of elastase increased the 
clearing rate of labeled albumin. Further, PE was traced to interruptions specifically in 
the tight junction structures that help in the creation of a tight monolayer of epithelial 
cells (86, 87). Therefore, an increased clearing rate of a substance in the lungs coincides 
with a decreased barrier function caused by PE addition. 
To help form regulatory barriers, the epithelial cells create intercellular junctions 
called tight junctions. Tight junctions are considered the ultimate gateway between the 
cells and the underlying tissues. The complexes that form tight junctions are composed of 
various proteins including occludin, claudin, and the cytoplasmic scaffolding proteins 
zonula occludens (ZO-1, -2, -3) (88, 89, 90). Disruption of the proteins that form the 
complexes for tight junctions can cause an adverse effect in the transport and filtering 
functionality of the epithelium (91, 92, 93). Therefore, as demonstrated previously, any 
alteration by bacterial toxins can interfere with normal barrier functions (94, 95). Madin-
Darby canine kidney (MDCK) epithelial cells demonstrated the ability of PE to perturb 
the function of the tight junctions by altering the concentration of ZO-1 proteins without 
membrane disruption. This indicated that PE has a toxic effect on the barrier function of 
epithelial monolayers and alters at least one protein in the tight junction complex (96). 
Further, virulence factors released from P. aeruginosa including PE and exotoxin A 
exhibited an ability to increase epithelial permeability by the measurement of Trans-
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epithelial Electrical Resistance (TER), however, during experiments with acute 
pneumonia, data suggested that PE breaks down tight junctions increasing its virulence. 
And in synergy with lipopolysaccharide (LPS), PE demonstrated an increase in epithelial 
permeability and facilitated the influx of neutrophils causing an inflammatory response 
(97, 98, 99, 100). 
II. Molecular Mechanism of the Disruption in Epithelia Integrity 
Since PE disrupts the function of tight junctions without resulting in cell injury or 
death, investigations to explain this effect were explored. A plausible theory pointed in 
the direction of host signaling pathways involved in the formation of tight junctions 
because previous research determined the ability of Pseudomonal proteases in stimulating 
the extracellular regulated kinase (ERK) signaling pathway, enhancing IL-8 production in 
vitro, and activating other inflammatory responses through certain protease-activated 
receptors (101, 102, 103). Therefore, an exploration in the role of PE on the pathway of 
tight junction formation was studied. It is known that tight junction assembly and sealing, 
cellular localization of occludin and ZO-1, along with the previous pathways described, 
are in part regulated by protein kinase C (PKC) signaling (104, 105, 106). Our lab 
incorporated a study that discovered the impact of PE-induced PKC signaling and the 
redistribution of the multifunctional complex that defines tight junctions. The results 
demonstrated PE pathogenesis targets occludin, ZO-1 and F-actin by elevating PKC 
levels and causing tight junction translocation and cytoskeletal reorganization (107). 
These experiments all elucidated the mechanistic action of PE on paracellular 
permeability and tight junction disruption. The next discoveries allowed for an enhanced 
explanation of this distinct effect on cell signaling.  
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III. Signal Transduction Pathways Involved in Pathogenesis of PE-induced injury 
 The epidermal growth factor receptor (EGFR) is a complex signaling pathway 
involving a number of signaling cascades. This receptor is common to many cell types 
including lung epithelium. Receptor tyrosine kinases, like EGFR, are transmembrane 
receptors composed of an intracellular domain, extracellular ligand-binding domain, and 
a transmembrane portion (108). The EGF family of receptors are initially activated via 
ligand-receptor complex formation. It is known that members of this family of tyrosine 
receptors are activated by a multitude of ligands including Epidermal growth factor 
(EGF), Transforming growth factor (TGF – α), heparin binding (HB)-EGF, amphiregulin, 
β-cellulin and epiregulin (109, 110). Once ligand bound, a conformational change occurs 
within EGFR, dimerization of the receptors, and then autophosphorylation of the tyrosine 
residues results. Transient phosphorylation of tyrosine residues on internal cellular 
substrates activates downstream signaling including phospholipase C-y (PLC-y), PKC, 
mitogen-activated protein kinases (MAPK), and ras GTPase-activating protein (GAP) 
(111). This ultimately leads to increased activity in angiogenesis, cell differentiation, 
proliferation, survival, progression of many cancers, and more recently reported 
regulation of tight junctions via PKC signaling (104, 105, 106, 112, 113, 114, 115).  
 A consequence of autophosphorylation of EGFR, as mentioned previously, is the 
activation of downstream elements like MAPK. Mitogen-activated protein kinases 
include ERK 1/2, ERK 3/4, ERK 5, ERK 7/8, c-Jun N-terminal kinase (JNK) 1/2/3 and 
p38 isoforms. It is known that ERK signaling is involved in cell proliferation and through 
extracellular transient activation by EGFR, can regulate tight junction protein assembly 
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and cytoskeletal rearrangement (116). Our lab demonstrated the ability of PE to activate 
the epidermal growth factor receptor and further elicit downstream activation of the ERK 
1/2 arm of the MAPK pathway within 5 minutes of apical exposure of Calu-3 cell 
monolayers. This activation preceded the disruption in tight junction structure by the loss 
of localization of occludin, ZO-1, and cytoskeletal reorganization (Castillo, Azghani, 
unpublished). Further, this ability of PE to activate this signaling cascade was revealed 
through inflammatory pathways that displayed an enhanced IL-8 production via NF-NB 
activation (117). 
 Another family of downstream signaling affected by EGFR activation is the Rho 
family of small guanosine triphosphate (GTP) – binding proteins. Rho proteins are 
identified to be important in the regulation of tight junction structure, function and 
assembly (115). This is important in the context of mediating Rho GTPases because 
previous studies of bacterial toxins on tight junction and actin cytoskeleton documented 
their ability to reorganize actin cytoskeleton, disrupt tight junction structure and function, 
and causing the formation of gaps in cell monolayers (100). This was further illustrated 
by additional studies displaying Rho protein importance in tight junction structure and 
function regulation (118, 119). Experiments ran in our lab verified a similar effect caused 
by PE on cell monolayers. RhoA GTPase was activated through EGFR and MAPK 
signaling by PE treatment on cell monolayers and confirmed by morphological analysis 
with fluorescent microscopy (Pal, Azhgani, unpublished). However, even with all the 
knowledge accrued, there are still questions that need to be answered. Therefore, new 
methodology in our lab seeks to make the studies of elucidating the mechanisms more 
efficient. 
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Goals of this Thesis 
• Synthesize a Recombinant Elastase 
• Measure and compare activity of Recombinant Elastase to commercial product 
• Define pathophysiologic effects of Recombinant Elastase in comparison to 
published data on P. aeruginosa Elastase 
Synthesizing a Recombinant Elastase 
I. History of Cloning and Recombinant Technology 
The process of molecular cloning dates to the late 1960s with the discovery of 
restriction endonucleases, better known as restriction enzymes, that possess the ability to 
cleave specific regions of DNA. With this molecular machinery, along with reverse 
transcriptase and polymerase chain reaction (PCR), recombinant technology expanded 
exponentially as techniques improved manipulating the genetic material. The basic 
concept in cloning involves (1) the isolation of coding DNA fragments through PCR 
amplification, (2) ligation of isolated DNA, termed inserts, into an appropriate plasmid 
genetic carrier, (3) transformation of plasmid into a suitable host for propagation, (4) 
screening and selecting for hosts containing the intended plasmid, and lastly (5) 
expression of recombinant protein in new host organism (120). The process of 
manipulating DNA and creating suitable recombinant hosts for expression is straight 
forward, however, the selection of primers, vectors, extraction techniques, percent yield, 
and activity of recombinant product defines the actual efficiency of any select protocol. 
Bever and Iglewski performed the first cloning and expression study of PE in 
1988. They utilized a pUC18 plasmid to transform E. coli. The specific E. coli employed 
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in this cloning process was the TB1 strain that has an hsdR mutation which allows for 
the efficient transformation of unmethylated DNA from PCR amplification. Further, 
they implemented an E. coli cell-free transcription-translation system that resulted in 
small amounts of gene products. Elastolytic activity was measured by 
spectrophotometry readings using Elastin-congo red (ERC) of total cell lysates (80). The 
next group of researchers that attempted to clone and express PE utilized an HB101 E. 
coli strain with pUC18. This strain displays high stability of recombinant vector, high 
efficiency of transformation, and doesn’t require a heat shock step. However, their 
representation of recombinant products does not account for purification technique or 
possible interaction by lipopolysaccharide (76, 77). More recent developments 
attempted the expression in a methylotrophic yeast, Pichia pastoria, which allowed the 
researchers to produce high yields of protein with an inexpensive induction promotor, 
AOX1, by methanol. Although yeasts produce a high yield of recombinants and are 
economically friendly, in comparison to E. coli, yeast are slow growers, protein 
production may take days versus hours, they must be produced immediately before use, 
and usually many clones need to be screened for protein production before a good 
producer is found (121).  
An improved cloning technique was presented in 2013 by utilizing a plasmid 
containing a 6-consecutive histidine residue tag and transforming E. coli BL21 for 
expression (122). The BL21 strain is deficient in Lon protease and OmpT protease and 
is therefore generally preferred for recombinant protein expression. Furthermore, this 
strain of E. coli contains an RNA polymerase that recognizes the lac promoter necessary 
for Isopropyl β-D-1-thiogalactopyranoside (IPTG) induced expression. However, Raftari 
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et al. (2013) used a 6x histidine tag for verification via western blot analysis. However, 
they state their recombinant product to be 53 kDa in size rather than the 33 kDa product 
that should be expected (122). 
The improvement of recombinant technology over time has dramatically 
increased our potential to create a more economically friendly enzyme, however, more 
work is necessary to produce an experimentally useful recombinant product. There are 
several concerns not accounted for with the previous research including 
lipopolysaccharide (LPS), efficient selection and ability to freeze stocks, easy 
purification techniques, correct size and activity of recombinant enzyme, and the ability 
to represent identical pathophysiological function to the naturally produced enzyme. 
Therefore, our overall goal is to improve the technology to account for these concerns 
and prove the existence of an identical recombinant Elastase product. 
II. Purpose of Developing a Recombinant P. aeruginosa Elastase 
 P. aeruginosa elastase has demonstrated an invalidating ability to cause 
detrimental effects to the human body through in vivo signs and symptoms, such as: 
edema, fibrosis of the lungs, tight junction disruption, increased paracellular 
permeability, and induced inflammatory responses. However, much research remains to 
elucidate the molecular mechanisms for the activation of the pathways involved. To 
further our laboratory’s research efforts, it was decided to clone and purify PE instead of 
purchasing the commercially produced and costly product. The purpose of this thesis is to 
offer an alternative process that is cost effective, efficient, and corrects for concerns from 
previous cloning techniques. This thesis elaborates on the ability to produce a 
recombinant PE that can be utilized for research purposes that further characterize the 
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precise nature of the previously studied effects in vitro and in an animal model of 
pulmonary infection and inflammation. This provides a laboratory setting that indubitably 
becomes self-efficient, an opportunity to reduce funding expenses for further project 
goals, and more knowledge in the process of PE production and characterization. 
Hypothesis 
 In this study, evidence is provided in support of the hypothesis that P. aeruginosa 
Elastase can efficiently and effectively be cloned and expressed in E. coli. The 
significance of this study proves the identity of the recombinant enzyme (RecE) produced 
in terms of enzymatic activity and physiologic effects in vitro. The hypothesis was 
addressed by DNA isolation from strains of P. aeruginosa that produce PE and cloning 
the gene responsible for PE, lasB, with specifically designed primers. Follow up 
biochemical analysis and in vitro studies confirmed RecE identity as well as its 
pathophysiological activity.
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Chapter Two 
 
Materials and Methods 
1) Bacterial strains: 
a) Pseudomonas aeruginosa: The strain of Pseudomonas aeruginosa (P. 
aeruginosa) is a clinical strain isolated from a patient positive for cystic 
fibrosis disorder (UT Health Northeast, Tyler, TX). For our experiments, 
this isolate was sub-cultured into 3 mL of Luria-Bertani (LB) broth at 
37°C for 24 hours before DNA isolation. 
 
b) Escherichia coli: Two separate strains of Escherichia coli (E. coli) were 
used in this experiment. The first strain, 10G electrocompetent; Lucigen, 
Radnor, PA, was used for plasmid amplification and second strain, 
ClearColi BL21; Lucigen, Radnor, PA, was utilized for protein 
expression. ClearColi is a genetically modified E. coli that contains an 
altered form of lipopolysaccharide that does not trigger an endotoxic 
response in human host. 
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2) Amplification of lasB gene: 
a) Bacterial genomic DNA isolation: Ultraclean® Microbial DNA Isolation 
Kit (Mo Bio Laboratories, Inc, Carlsbad, CA) was used to isolate bacterial 
DNA according to the manufacturer’s protocol. DNA was analyzed for 
purity using a Thermoscientific NanoDrop 2000 Spectrophotometer 
(ThermoFisher, Waltham, MA) to assess the quality of the isolated DNA. 
P. aeruginosa DNA was evaluated by absorbance at 260 nm. 
 
b) Primer Design: Primers used for amplification of the LasB gene (P. 
aeruginosa Elastase coding gene) were the Forward LasB and Reverse 
LasB primers as follows: 
5’>GCGCCCATGGGCAAGAAGGTTTCTACGCTT<3’ (sense primer 
containing ATG start codon), containing a NcoI restriction site and 
5’>CGCGGGATCCCAACGCGCTCGGGCA<3’ (anti-sense primer), 
containing a BamHI restriction site (Eurofins Genomics, Louisville, KY). 
The highlighted regions contain the restriction enzyme recognition sites. 
These primers were developed by analyzing the beginning and end of the 
publicly available gene sequences for LasB on GenBank. The gene was 
amplified by Polymerase Chain Reaction (PCR) utilizing the PfuUltra II 
Fusion HS DNA Polymerase (Agilent Technology, Santa Clara, CA) in a 
Bio-Rad T100 Thermal Cycler (Bio-Rad Laboratories, Hercules, CA). 
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PCR specifications were: Heating at 95qC for 5 minutes, Initial 
Denaturation at 95qC for 30 seconds, Annealing at 52qC for 30 seconds, 
Elongation at 72qC for 5 minutes, and 40 rounds. After amplification, the 
product was analyzed using agarose gel electrophoresis and sent for 
sequencing to Eurofins Genomics (Louisville, KY) to verify the amplified 
gene. The recombinant lasB gene sequence was deposited in the NCBI 
GenBank database (accession number KY861927). 
 
3) Transformation of E. coli: 
a) Digestion and Ligation with bacterial plasmid: The pET28b plasmid 
(Novigen Sciences, Inc, Washington, DC) was utilized for LasB gene 
incorporation, which installed the sequence tag containing 6 histidine 
residues (6xHis tag) to the C-terminus of Recombinant Elastase (recE) 
allowing single column purification by nickel affinity chromatography. 
Amplified LasB gene and pET28b vector were digested with NcoI and 
BamHI restriction enzymes (New England Biolabs, Ipswich, MA). The 
digested LasB gene and pET28b vector were purified using the Qiagen 
MinElute Reaction Cleanup Kit (Qiagen, Hilden, Germany). Purified 
LasB and pET28b were mixed and ligated with T4 DNA ligase (New 
England Biolabs, Ipswich, MA) according to the manufacturer’s 
directions. Subsequently, the ligation mixture was transformed into E. coli 
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10G electrocompetent cells (Lucigen, Radnor, PA) by electroporation 
using an Eppendorf Eporator (ThermoFisher, Waltham, MA). Cells were 
grown on an LB agar plate containing kanamycin (50 µg/mL) for selection 
of the pET28b plasmid. Colonies were screened for the presence of LasB 
via colony PCR and positive hits were subsequently grown up in LB 
broth. The DNA was extracted from selected colonies and sent for 
sequencing (Eurofins, Louisville, KY). Plasmids with a confirmed 
sequence for LasB were transferred into ClearColi (Lucigen, Radnor, PA) 
and successive expression experiments were carried out.  
 
b) Inductive Expression of Recombinant Elastase: For expression, 5 mL LB 
broth cultures containing kanamycin were inoculated and grown overnight 
at 37°C. These cultures were later transferred to 1 L shaker flasks that 
were sterilized and made lipopolysaccharide (LPS) free by baking at 
350°C for 3-4 hours. We incubated the flasks with shaking at 250 rpm at 
37°C. Upon reaching an OD600 between 0.6 – 0.8, cells were induced with 
0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Carbosynth, San 
Diego, CA) and allowed to incubate overnight at a reduced temperature of 
30°C. Cells were harvested by centrifugation (Rotor TA-14-50, Beckman 
Coulter, Allegra 25R Centrifuge) and stored at -20°C until purification. 
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4) Protein Harvest and Purification: 
a) Cell Lysing: Harvested cells were thawed at 4°C and resuspended in Lysis 
Buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4). Lysis was carried out 
by sonication in a 50 mL conical tube on ice using a Qsonica Sonicator 
(Qsonica, LLC, Newtown, CT) with 70% amplitude, a process time of 5 
minutes, pulse-on for 1 second, and pulse-off for 2 seconds. After 
sonication, the whole-cell lysates were centrifuged (Rotor TA-14-50, 
Beckman Coulter, Allegra 25R Centrifuge) at 14,000 rpm for 40 minutes 
at 4°C to separate the insoluble cell matter from soluble supernatant 
containing our recombinant Elastase (recE). 
 
b) Fast Protein Liquid Chromatography (FPLC): Purification of recE was 
performed on a Bio-Rad FPLC NGC Chromatography System (Bio-Rad, 
Hercules, CA) the supernatant was applied to a nickel-nitrilotriacetic acid 
(Ni-NTA) affinity column pre-equilibrated with Wash Buffer (50 mM 
Tris, 300 mM Sodium Chloride, pH 7.5) using a DynaLoop 90 (Bio-Rad, 
Hercules, CA). Subsequently, the column was washed with 10 column 
volumes of Wash Buffer, then 10 column volumes of low concentration 
imidazole buffer (50 MM Tris, 300 mM Sodium Chloride, 25 mM 
Imidazole, pH 7.5), to remove non-specifically bound proteins, before 
final elution with Elution Buffer (50 MM Tris, 300 mM Sodium Chloride, 
250 mM Imidazole, pH 7.5). During the elution process, absorption of 
eluent was monitored with Bio-Rad FPLC NGC Chromatography System 
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(Bio-Rad, Hercules, CA) and fractions collected with a BioFrac Fraction 
Collector (BioRad, Hercules, CA). Fractions showing strong absorption at 
280 nm were kept for analysis on a 12% Sodium dodecyl Sulphate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) using a Mini-Protean 
electrophoresis apparatus (BioRad, Hercules, CA) to verify the molecular 
weight of the purified product expected to contain recE. The recE 
containing fractions (~33kDa) were combined and dialyzed 4x with Tris 
Buffer (5 mM Tris-HCl, 0.5 mM Calcium Chloride, pH 7.5) for four hours 
each time to reduce the imidazole concentration. The dialysis tubing was 
45 mm in width, 29 mm in diameter, and contained a molecular weight 
cutoff (MWCO) of 3,500 (Sigma-Aldrich, St. Louis, MO). Once dialysis 
was complete the recombinant solutions were centrifuged at 13.3 rpm for 
10 minutes to remove any precipitated matter (inactive enzyme). Then, the 
final concentration of recE per solution (mg/ml) was determined by UV-
Vis absorption with Thermoscientific NanoDrop 2000 Spectrophotometer 
(ThermoFisher, Waltham, MA). The Extinction Coefficient (H) was 
calculated by translating the gene sequence to amino acids using an online 
DNA Translator (fr33.net) and subsequently using the software program 
Protein Calculator v3.4 (C. Putnam, The Scripps Research Institute, 
U.S.A.) to determine H at A280 Molar Extinction with all disulfides. 
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5) Recombinant Elastase Activity Assessment: 
a) Proteolytic Activity: Proteolytic activity was assessed by Skim Milk Agar 
Diffusion Plate analysis using varying concentrations of recE solution 
(7.36U/ml, 3.68U/ml, 1.84U/ml, and 0.74U/ml). Petri-dishes containing 
1.5% skim milk powder and 1% agar were used to place round filter 
papers loaded with 10 PL of recE solution and observed for casein 
diffusion every 30 minutes for 4 hours, then overnight. 
  
b) Elastolytic Activity: Elastolytic activity was assessed by Elastin-Congo 
Red Assay (ThermoFisher, Waltham, MA) by two separate methods. In 
the first method and step, a standard Optical Density (OD) per mg of 
elastin using Porcine Pancreatic Elastase (Worthington Biochemical 
Corporation, Lakewood, NJ) was developed to compare our recE for 
activity. Varying concentrations of elastin substrate (0, 2, 4, 6, 8, and 10 
mg/ml) were added to 1 mL eppendorf tubes with constant volumes of 
Porcine Pancreatic Elastase (50 PL/ml) and left on a shaker for 1 hour at 
37°C. OD was determined by spectrophotometry at A485 using the Bio-
Rad SmartSpec Plus spectrophotometer (BioRad, Hercules, CA) and the 
average OD per mg substrate was calculated (+/- 5%). In step two, we ran 
an activity assay for our recE unknown by keeping the concentration of 
enzyme constant (50 PL/ml mixture) and increasing amounts of the elastin 
substrate (0, 2, 4, 6, 8, 10 mg). This elastolytic assay ran on a shaker for 1 
hour at 37°C before reading OD. An OD per mg RecE was calculated to 
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determine if enzyme displayed a linear increase in solubilization with 
increasing substrate. To determine the mg of substrate solubilized, the OD 
readout was subsequently divided by the standard OD per mg substrate 
previously determined in the first step. Then, the units of activity per mg 
of recE was calculated by dividing the mg of substrate solubilized by the 
mg of recE used. One unit of activity equals the mg of elastin solubilized 
in 1 hour at 37°C. Equation 1 below demonstrates the previously 
mentioned calculations. 
 
Equation 1: 
Units/mg = mg Substrate Solubilized/ mg Elastase = (OD Observed)/(OD/mg Substrate) 
 
The second method to analyze elastolytic activity utilized the same 
methodology listed above except for being read at 495 nm for absorbance. 
Following OD readouts, specific activity was determined by dividing the 
activity of the recombinant elastases by the activity of the commercial 
elastase and subsequently multiplying by 100 to represent a percentage. 
 
6) Virulence activity of RecE in vitro: 
a) Cell Culture: A human bronchial adenocarcinoma epithelial cell-line 
(Calu-3, ATCC; Manassas, Virginia) was used as an in vitro model to 
study the physiological effects of RecE. The cells were cultured and 
maintained in Dulbecco's Modified Eagle's Medium (Gibco, Life 
Technologies, Grand Island, New York) at 37°C in a humidified 
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atmosphere of 5% CO2 / air. The medium was supplemented with 10% 
Fetal Bovine Serum (FBS; Atlanta Biologicals, Lawrenceville, GA), 1% 
L-glutamine (Cellgro, Herndon, VA) and an antibiotic mixture of 10% 
Penicillin (100Pg /ml). Cells were maintained in tissue culture flasks 
(Corning, Corning, NY) and were discarded after being passaged 20 times. 
The medium for the flasks was changed every other day to avoid nutrient 
depletion. Trypsin/EDTA (0.25%, Gibco, Life Technologies, Grand 
Island, NY) was used to transfer the cells from flasks to the appropriate 
cell culture ware according to the experimental design. 
 
b) Impact on Cell Morphology: To identify morphological changes in 
response to concentration and time of treatment with RecE, 24-well cell 
culture cluster plates (Costar, Corning, NY) were seeded at 1x105 cells 
with Calu-3 cells and grown to confluency before experimentation. Cells 
were serum-starved overnight (12 hours) before subsequent treatment with 
varying concentrations of RecE (1-8 U/ml) and observed using a Nikon 
TMS Inverted Microscope (Nikon, Tokyo, Japan) every 15 minutes for 2 
hours. Images were captured using 8 MP, f/2.2, 29mm, phase detection 
autofocus Apple camera at 200x total magnification (Cupertino, CA). 
 
c) Immunofluorescence microscopy: Fluorescence microscopy was employed 
to investigate the subcellular distribution of target tight junction proteins 
in Calu-3 cells during Recombinant Elastase exposure. Calu-3 cells were 
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seeded into Lab-Tek Chamber Slides an 8 Well Permanox system 
(ThermoFisher, Waltham, MA) at 1x105 cells per chamber. Cells were 
treated with 1-2 U/ml of RecE for up to 90 minutes and a control (Carrier 
MEM alone) for 90 minutes. Following treatment, cells were washed with 
Phosphate Buffered Saline (PBS) 2x and fixed with 4% fresh 
paraformaldehyde solution in PBS for 10 minutes at room temperature. 
After an additional 2x wash with PBS, cells were permeabilized with 0.1% 
Triton X-100 in PBS for 5 minutes at room temperature. The cells were 
washed 2x with PBS before being blocked with 1% bovine serum albumin 
(BSA) for 1 hour at room temperature. After blocking, the monolayers 
were incubated with FITC conjugated Mouse Monoclonal Antibody 
against ZO-1 (10Pg/ml; Invitrogen, Carlsbad, CA) at room temperature for 
60 minutes in the dark. The monolayers were washed 2x with PBS before 
the addition of secondary antibody (Goat anti-Mouse IgG) conjugated 
with Alexa Fluor 488 (10Pg/ml; ThermoFisher, Waltham, MA) at room 
temperature for 60 minutes in the dark. The monolayers were then washed 
2x with PBS and then mounted using ProLong Gold antifade 
(ThermoFisher, Waltham, MA) before microscopic observation. The 
monolayers were examined under Zeiss LSM 5 Pascal Laser scanning 
Confocal Microscope equipped with an Axiocam HRc Color Digital 
Camera (One Zeiss Drive, Thornwood, NY). Photomicrography was 
performed under 500x total magnification with oil and images were 
captured for visualization in LSM software by Zeiss. Differences in the 
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localization of tight junction protein, Z0-1, were visually observed and 
documented.
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Chapter Three 
 
Results 
 
Cloning and Sequence Analysis of Recombinant Elastase Gene from P. aeruginosa 
 
 The coding gene for P. aeruginosa Elastase (lasB) was amplified from the 
genomic DNA of two separate strains of P. aeruginosa, a clinical strain (from our clinical 
isolates collection from CF patients) and PAO1 from ATCC. It is reported that some 
strains of P. aeruginosa do not produce elastase, therefore, two strains were utilized to 
confirm for the elastase gene contained in the genome. An Ultraclean® Microbial DNA 
Isolation Kit (Mo Bio Laboratories, Inc, Carlsbad, CA) was used to isolate the genomic 
DNA. Purified DNA was verified by NanoDrop for quality and respective absorbance 
was read at 260 nm. Forward and reverse primers were designed based on the nucleotide 
sequence coding elastase from P. aeruginosa reported in GenBank Accession no. 
M194721 followed by amplification. Figure 1 demonstrates the amplification
 32 
products of the two strains of P. aeruginosa. The amplified product following PCR was
 
comparable to the reported size of the lasB gene of 1,491 base pair. 
The Clinical strain displayed a higher amplification product and was thus the only 
strain used in the rest of the experimentation. After amplification of the lasB gene, a 
process of digestion and ligation was performed to insert the newly synthesized PCR 
product into the pET28b plasmid. Initially the amplification product from Fig. 1 would 
not properly ligate into the pET28b plasmid vector until the required conditions of 
ligation and digestion were optimized. Ligation reaction was used to transform an initial 
Figure 1: Agarose gel electrophoresis displaying PCR amplification of the lasB gene: 
The amplified DNA sequences from Clinical and Laboratory strains PAO1 of 
Pseudomonas aeruginosa displayed a PCR product approximately the size of native 
elastase gene (1,491 bp). 
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electrocompetent cell line of E. coli known as 10G Electrocompetent cells. Integration of 
plasmid provided kanamycin resistance that allow for screening for incorporation within 
cells. Figure 2 demonstrates the correct band size (~1,500 bp) for the lasB gene, from 
colony 28, in lane 5 following colony PCR of randomly selected 10G Electrocompetent 
cells expressing kanamycin resistance.  
Each well was loaded with 10 Pl of sample (S1 – S5) or molecular weight 
markers and gel ran for 45 minutes before visualization. Several of the colonies present 
on the plates were resistant to kanamycin but did not contain the recombinant gene as 
visible in the gel electrophoresis in lanes 1-4 of Fig. 2. After gel electrophoresis of our 
recombinant gene confirmed the size, colonies were grown up, DNA extracted, and sent 
for sequence confirmation through Eurofins in the forward and reverse direction. Figure 3 
Figure 2: Recombinant lasB gene expression in Electrocompetent cells: Agarose gel 
electrophoresis after ligation and transformation into 10G Electrocompetent cells and 
colony PCR. Lane 1 is the Molecular Weight Ladder, Lanes 2-4 were not clones, and 
Lane 5 shows the proper length of the lasB recombinant gene at approximately 1491 
bp.  
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displays the result we received after splicing the gene sequences together from the 
forward and reverse runs. 
 The entire sequence return was 1,557 nucleotides in length and a 1,497 base-pair 
product was obtained after removing the histidine residue sequences and the bases coding 
for thrombin (for removal of tag) located immediately in between the end of the sequence 
and the histidine tag. This product corresponds directly to the product size on a previous 
Figure 3: Sequence results of the recombinant lasB gene match lasB in GenBank: The 
above sequence is the resulting sequence obtained from Eurofins. Vertical line: 
beginning and end of gene; Green font: start codon; Purple font: base changes. The 
obtained 1557 bp recombinant nucleotide sequence contained homology with lasB 
from P. aeruginosa PAO1 (GenBank Accession no. M194721).  
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study attempting to clone lasB into Picha pastoris GenBank Accession no. EU265777. 
The start codon is highlighted in green and the vertical lines mark the beginning and end 
of the lasB gene displayed in Fig 3. Compared with the other elastase gene sequences 
reported in GenBank, the nucleotide sequence of the cloned DNA shares 99% homology 
with lasB from P. aeruginosa PAO1 (GenBank Accession no. M19472.1) (Figure 3). 
Only four bases changed (336 CoT, 1029 ToC, 1110 AoT, 1122 CoT) were observed 
as highlighted in purple of Fig 3. Regardless, when translated, there was no difference 
between deduced amino acid sequence and native elastase from P. aeruginosa.  
Figure 4 displays the resulting amino acid sequence from our gene sequencing 
data.  
The importance of translating the code to amino acids is to present the presence of 6 
concurring histidine residues that served as a tag when we purified through the Ni-NTA 
Figure 4: Complete amino acid sequence of recombinant lasB gene containing the 6x 
His-tag: The amino acid sequence was translated from the coding strand of the RNA 
template of the recombinant lasB gene. The sequence contains identity comparable to 
the naturally produced elastase and contains 6 histidine residues at the end for our 
purification tag (blue font).  
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liquid chromatography system. Our recombinant gene displays the histidine residues, 
highlighted in blue, necessary for this step. 
Expression of Recombinant Elastase in ClearColi 
 
 DNA was extracted from the 10G Electrocompetent cells and subsequently 
introduced into our expression vector ClearColi. Post induction with IPTG, ClearColi 
were incubated overnight at a reduced temperature of 30°C before cell harvest. We 
utilized this induction condition to optimize the production efficiency. Under these 
conditions, ClearColi expressed about 1.083 mg recE/L of cells.  
After the expression incubation on the shaker, the cells were subsequently 
harvested by sonication and recombinant products separated from the cell debris by 
centrifugation. The supernatant was harvested and through a process of Ni-NTA liquid 
chromatography, our recombinant elastase was collected and purified as detailed in 
methods. The different methods were utilized for protein purification. The initial batch of 
recombinant elastase used a standard chromatography column with Ni-NTA liquid 
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chromatography and fractions were collected manually as depicted in Figure 5.
  
 Ten Pl of each collected fraction was added to the SDS-PAGE wells in Fig. 5 and are in 
order from first collected eluent to last. As expected, lanes 3 through 6 contained the 
highest concentration (mg/ml) of recombinant proteins displaying correct size (~34 kDa).  
 The second (RecE2) and third (RecE3) batch of recombinant elastase were 
purified using a fast protein liquid chromatography system (FPLC). The fractions were 
automatically analyzed and collected during the elution process. Only fractions 
containing the recombinant elastase displaying proper absorbance (280 nm) were 
Figure 5: SDS-PAGE analysis of fractions from Ni-NTA chromatography of 
recombinant elastase: The gel displays the correct size of elastase (34 kDa) and pro-
elastase (55 kDa) with various smaller fragments (~17 kDa).  
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combined, dialyzed, and finally centrifuged to remove precipitates/impurities. 
  
In Figure 6, a confirmation test was performed to assess and compare the size of our 
recombinant elastase to that of the commercially available one. The observed size (34 
kDa) validates both recombinant elastase batches match that of the naturally produced 
and commercially available elastase. According to the SDS-PAGE analysis, the 
recombinants and commercial produce banding at 34 kDa. The extinction coefficient for 
RecE (ε, λ 280 nm) was 60,690 M-1cm-1 or 1.0937 (mg/ml)-1 cm-1. 
 
 
 
 
Figure 6: SDS-PAGE analysis of recombinant elastase post removal of precipitates: 
Lane 1 is the Molecular Weight Ladder, Lanes 2 and 3 contain the recombinant protein, 
and Lane 4 contains the commercially available Pseudomonas Elastase (34 kDa).  
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Enzymatic Activity of the Recombinant Elastase 
 
We employed two different biochemical methods to confirm the proteolytic as 
well as the elastolytic activity of the RecE product. Skim milk agar plates were designed 
with round filters saturated with four different concentrations of RecE as labeled in 
Figure 7. This test was used to identify the ability of RecE to proteolytically cleave casein 
contained in the skim milk plates. As observed in Fig 7, RecE contains high proteolytic 
activity. 
 
The units of activity were then assessed using Elastin-Congo red as the substrate 
and subsequently calculated for Fig 8. The round filters (1-4) contained 1083.0, 541.50, 
270.75, 135.37 Pg/ml respectively. As presented in Fig 7A, RecE proteolytic activity was 
observed as hydrolysis areas, or transparent zones, within 5 minutes of the addition to the 
round filters. This was monitored every thirty minutes for a total of four hours and then 
imaged again at 24 hours post addition (Fig. 7B). The clearing zones were evidence of 
the ability of RecE to degrade the casein within the skim milk agar plates.  
Figure 7: Proteolytic activity of the Recombinant Elastase in Skim milk agar 
diffusion plates: The plate displayed clearing zones around filter papers loaded with 
10 Pl of varying concentrations of RecE as indicated. Image A shows the ability of 
RecE to degrade casein at 5 minutes and after 24 hours (Image B). 
 
 40 
 Once proteolytic activity was determined, the ability of the recombinant enzyme 
to degrade elastin was verified by Elastin-Congo Red (ERC) substrate assay. To test this, 
a standard curve was constructed and used to determine the Optical Density (OD) per mg 
of substrate solubilized in an hour at 37°C. With this knowledge, the amount of substrate 
solubilized by our recombinant elastase was calculated by adding known concentrations 
of substrate and RecE and then comparing the observed OD to the standard.  
 Elastolytic activity (in units) was determined by combining 50 Pl of RecE and 10 
mg of ERC substrate in 1 ml reactions. As a control and comparison, the commercially 
obtained elastase produced by P. aeruginosa was included in the protocol recommended 
by the manufacturer. The substrate solubilized for each reaction was determined by 
dividing the observed OD by the previously determined standard OD/mg substrate. From 
this value, the units of activity per mg of elastase (Units/mg elastase) was determined by 
dividing the mg substrate solubilized by the mg of elastase utilized. Table 1 compares the 
activity of the two recombinant elastases in comparison to the commercial. This 
experiment was performed in triplicate and the results presented as the means +/- 
standard deviation.
 
Table 1: Units of activity for RecE in comparison to commercial elastase: Both batches 
of RecE (RecE2 and RecE3) present increased activity in comparison to the commercial 
PE. Asterisks represent significant values from commercial. 
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Specific activity was determined by dividing the activity of the recombinant elastases by 
the activity of the commercial elastase. Specific activity is defined as the change in 
optical density (OD) at A485 per hour/mg of elastase written as a percentage in 
comparison to the commercial. As represented, we discovered RecE had a significant 
increase in activity in comparison to the naturally produced as evident by significant p 
values of student’s t-test (p<0.05) for both batches.  
 In previous studies, elastolytic activity was determined at A495 rather than A485. 
We utilized this same strategy to compare our product to previous research on cloning 
elastase. As Table 2 depicts, the specific activity of our RecE in comparison to our 
commercial is about a two-fold increase.  
This experiment was performed by using a constant known concentration of elastase 
(recombinant or commercial) and 10 mg of ERC substrate. The reactions were left on a 
shaker for 1 hour at 37°C before being placed in ice and subsequent absorbance read by 
spectrophotometer. The experiment was performed in triplicate and the results presented 
as an average of the three trials. Specific activity is defined as the change in optical 
density (OD) at 485 nm/hour/mg of elastase written as a percentage in comparison to the 
Table 2: Recombinant Elastase (RecE2 and RecE3) presents increased activity in 
comparison to the commercial Pseudomonas Elastase. Asterisks represent significant 
values from commercial. 
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commercial. Significant increases were determined using student t-test’s comparing the 
specific activity of the commercial to the recombinants +/- standard deviation (p<0.05). 
 Activity was further characterized by demonstrating the ability of RecE to digest 
Elastin-Congo red substrate in a linear fashion. Reaction mixtures containing constant 
concentration of recombinant elastase and increasing values of substrate were combined. 
The OD was read at A485 after 1 hour at 37°C. Figure 8 depicts both recombinant batches 
having a linear relationship between the OD/mg elastase and the mg of substrate present 
in the reactions. 
A trend line was fit to the data showing a linear forecast if substrate is increased. R2 
values were calculated and this determined our lines represent a predictive model for 
activity (RecE2, 0.95; RecE3, 0.97).  
Virulence activity of RecE in vitro 
 The purpose of performing the following experiments was to demonstrate the 
ability of our RecE to function identically to the commercial elastase in vitro. Calu-3 
monolayers were treated with various concentrations of Recombinant Elastase (1-8U/ml). 
These units of activity values reflect those of previous experiments in our lab.  Figure 9 
Figure 8: RecE demonstrates substrate linearity: A linear projection line with respective 
slopes and R2 values indicate a linear relationship between the OD readout and Elastin-
Congo red substrate added. 
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demonstrates the time course ability of a concentration at 2U/ml of Recombinant Elastase 
to make subtle morphological changes to Calu-3 cell anatomy in 2 hours. 
 
Monolayers were observed and images captured in 15 minute intervals for 2 hours. 
Figure 9 details that an in vitro examination of Recombinant Elastase displays similar 
physiological changes at low activity concentrations to the commercial Elastase. Figure 
10 demonstrates the concentration effect of a RecE on the cell anatomy and monolayer. 
In comparison to 2U/ml, this higher concentration shows substantial morphological 
changes and cell detachment at 60 minutes and complete disruption by 2 hours.  
 
Figure 9: Time Course Analysis of the Effect of Recombinant Elastase on cell 
monolayers: Calu-3 cell monolayers were treated with 2 U/ml (a physiologic 
concentration) of RecE and images captured at 15 minute intervals for 2 hours (200x 
total magnification). Sublet morphology alterations were apparent after 60 minutes. 
Cell detachment was minimally observed at 120 minutes.  
 
 44 
 
Molecular Alterations in Tight Junction 
We chose 1 or 2 U/ml of RecE activity for Immunofluorescent observations of tight 
junction protein, ZO-1, localization. ZO-1 is one of the proteins contained in the tight 
junction complex of cell monolayers. Therefore, normal expression of this protein is on 
the periphery of the cells to function as a barrier between the basal and apical surfaces. 
 Immunofluorescent (IF) analysis of ZO-1, a tight junction complex protein, 
localization was performed on Calu-3 cell monolayers in chamber slides. The cellular 
architecture was studied under immunofluorescent microscopy to look for changes after 
treatment with 1 or 2U/ml of Recombinant Elastase-2. Figure 12 displays the localization 
effect of treatment with Recombinant Elastase on ZO-1 (630X total magnification).  
Figure 10: Dose Response Analysis of RecE Effect on cell monolayers: Calu-3 cell 
monolayers were treated with 8 U/ml of RecE and images captured at 15 minute 
intervals for 2 hours (200x total magnification). Morphological changes and cell 
detachment were apparent within 30 minutes. 
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As presented by the IF results, the control displayed a uniformly distributed ZO-1 protein 
in cell peripheries. In treated cells, however, the continuous ring of ZO-1 was replaced by 
punctuate structures indicating degradation or relocation of the proteins. Therefore, ZO-1 
organization is both a time-and dose-dependent effect of Recombinant Elastase treatment. 
These results complement the data reported in the lab’s earlier research utilizing the 
commercial Elastase (107). 
 In conclusion, a Recombinant Elastase was cloned and expressed that properly 
reflects the size and enzymatic activity of the commercially available product from P. 
aeruginosa. The ability of RecE to cause anatomical changes in vitro via morphological 
and immunofluorescent analysis was characterized. Together, these results demonstrate 
Figure 11: Immunofluorescence of Tight Junction Protein, ZO-1, localization after RecE 
treatment: Calu-3 cell monolayers were treated with RecE and images captured (630X 
total magnification). According to analysis, ZO-1 localization is time and dose 
dependent. 
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the ability to utilize the above protocol to produce and efficiently create a recombinant 
enzyme for further studying the pathophysiologic effects of P. aeruginosa elastase. 
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Chapter Four 
Discussion 
In this thesis, the goal to synthesize a Recombinant Elastase that is comparable to 
the commercially available elastase produced by P. aeruginosa was successfully 
accomplished.  A recombinant lasB gene was cloned, inserted into pET28b plasmid, 
transformed electrocompetent recombinant expression E. coli, and purified a 
recombinant, active enzyme. Herein, this discussion describes the key points throughout 
the cloning process, improvements, and future research extensions.  
Initially, it was planned to utilize two strains of P. aeruginosa during the cloning 
process. However, only the clinical isolate following amplification via PCR as the lasB 
gene of this strain had more amplification as assessed by the gel electrophoresis (Fig 1). 
This strain was isolated from patients with chronic infections of P. aeruginosa and likely 
contains an increased resistance to antibiotics. Furthermore, after sequencing the 
recombinant lasB gene sequence, the final product contained four base-pair changes in 
comparison to the listed sequence on GenBank. This comparison of the gene sequences 
suggests that the difference in nucleotide sequence may be attributed to strain diversity 
which can also account for increased virulence (122). 
An IPTG lac operon promoter system was utilized for expression of the RecE 
protein. IPTG is a biological reagent that mimics allolactose in triggering the 
transcription of the lac operon. The first improvement in the cloning process involved the 
chosen plasmid, pET28b, which contains the lac operon along with nucleotides coding 
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for a 6x histidine tag. This improvement allowed for a Ni-NTA liquid chromatography 
system containing resin with a high affinity for histidine residues to successfully purify 
the RecE with high efficiency as detailed in Figs 5 and 6. Further, the induction process 
was enhanced, which improved the gene expression level by manipulating the 
temperature from the standard 37ºC to 30ºC to improve the low expression in the first 
few trials. In this case, the bacteria might be overwhelmed by production of the enzyme. 
Published research indicates the host strain does not prefer recombinant expression of 
proteases, therefore, potentially causing inclusion bodies to develop (123). Thus, to 
alleviate the stress mechanism caused by the overexpression of cloned genes in E. coli, an 
altered growth condition was performed during gene expression to improve the negative 
host response. Subsequently, modification in temperature increased the production of 
RecE and allowed for effective synthesis of a recombinant product. 
Another challenge was the contaminating proteins that were observed at the high 
(55 kDa) and low (~17 kDa) banding presented in Fig 5. Pseudomonas produces the 
enzyme elastase as a pro-form protein of 55 kDa before being cleaved and subsequently 
activated upon release as a mature 33 kDa elastase, with loss of a 22 kDa fragment. The 
observed banding support the presence of pro-form elastase and fragments from its 
cleavage to produce the mature elastase. To improve production of mature elastase, lower 
temperature expression was performed and the protein was purified by Ni-affinity 
chromatography. Subsequent centrifugation to remove precipitates that formed after 
overnight storage of Ni-affinity purified protein produced RecE representing a clean, 
finished product, as judged by SDS-PAGE (Fig 6). These results suggest that the source 
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of the contamination stemmed from either degradation of the RecE, proenzyme, and 
potentially recombinant enzyme that was no longer enzymatically active. 
The activity of the RecE was assessed to determine if RecE retained the published 
properties of the commercial enzyme. Using Skim milk agar diffusion plates and an 
Elastin-Congo red substrate assay the proteolytic and elastolytic activities of the 
recombinant enzyme was validated. The plates containing skim milk displayed clearing 
zones proving that the RecE can degrade casein as a proteolytic enzyme. From the 
Elastin-Congo red assay assessment, the RecE demonstrated an ability to degrade elastin. 
Astoundingly, RecE displayed an increased elastolytic ability in comparison to the 
commercial enzyme. This is important because enhanced activity can allow investigators 
to use less of the enzyme when studying its effects on lung tissue. 
The elastolytic activity confirms the biochemical property of the RecE enzyme. 
Therefore, an assessment of whether RecE manipulated cell anatomy in a time and dose-
dependent manner was examined. Microscopic evaluation of the cultured cells 
demonstrated that the RecE’s alters the cell morphology in a dose and time dependent 
manner (Fig 9 and 10). The Azghani lab has shown that minute amounts of Pseudomonas 
Elastase are produced in vivo and this small amount minimally alters the lung epithelium 
(86, 98). As such, this subtle change in the host cell morphology by a physiologic 
concentration of RecE mimics previous findings. Therefore, morphological analysis 
helped determine the time and dose of RecE to properly emulate the natural observation 
in patients for the next examination using immunofluorescent studies. 
Pseudomonas elastase has demonstrated an ability to alter the tight junction 
complex by manipulation of the ZO-1 protein (107). Through immunofluorescent 
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analysis using cell culture slides, the ability of RecE to manipulate the tight junction 
complex through ZO-1 reorganization or disruption was preliminarily verified (Fig 11). 
This validates previous studies from the Azghani lab that observed the same effect with 
the commercial elastase. In normal cell monolayers, the tight junctions are located 
uniformly on the periphery. However, with the addition of RecE, the ZO-1 protein is 
fragmented in its expression. Future studies should evaluate the manipulation of cell 
monolayers by RecE with Trans-epithelial Electrical Resistance (TER) analysis to 
confirm the immunofluorescent data presented in this project. In vivo studies will confirm 
the impact of RecE –induced alterations in tight junction complex in pathologic 
conditions including pulmonary edema.  
In summary, the goals of this thesis were successfully achieved by completing the 
project on recombinant enzyme synthesis and extensively evaluating the activity of the 
RecE. The preliminary data reported here is only the beginning of using RecE to 
elucidate the pathophysiological effect on lung tissue. This product can effectively be 
utilized in the Azghani laboratory and potentially made into a commercial product for 
other labs to use in their respective research. The next step in this line of research will be 
examining the effect of RecE on paracellular permeability through Trans-epithelial 
Electrical Resistance (TER) and biochemical analysis, such as, western blot for ZO-1. 
Earlier research in the lab determined that treatment with elastase from P. aeruginosa 
transiently causes the activation of the Epidermal Growth Factor Receptor (EGFR) 
resulting in downstream physiologic effects such as inflammation and edema (99, 107). 
The exact mechanism for the activation of the EGFR receptor by PE is still unknown and 
therefore, RecE can be used to elucidate whether the activation is direct through 
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attachment or an indirect fashion through potential cleaving of extracellular pro-ligands. 
This will allow for alternative therapy options to be developed to either inhibit the 
activation of EGFR and/or potentially using monoclonal antibodies to neutralize 
Pseudomonas Elastase (99). The ultimate goal is to develop a method to better treat 
patients suffering from infections by this bacterium and hopefully this finding provides 
an opportunity for the Azghani laboratory and others to more efficiently study the 
pathogenesis of lung injury by P. aeruginosa elastase.
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